SecBot SecBot

FTH

Faeth Therapeutics, Inc.
Nasdaq· CIK 0001829802 Biotech & Drug Discovery
$9.28 −0.75 (−7.48%)
Nov 16 4:00 PM ET · prev $10.03
Market cap
$275.2M
Micro cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
$56.00
+503% · range $40.00–69.00
1 year
+14.0%
from $8.14 · Nov 17
30 days
−52.3%
from $19.44
52-week range
$7.89–40.05
−77% from high · low Dec 15
Avg volume 20D
738.1K
Nov 9 spike 4.05M
Short interest
2.73M
≈10.6% of shares · +17.7%
Days to cover
6.3
at average volume
Insider net
+$1.2M
2 buyers · 0 sellers · 12 mo
New fund stakes
3
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 2 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 6/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $1.2M at an average $24.02. No open-market sales. Price is 61% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 12 added (3 new), 1 trimmed or exited. Largest new: Avoro Capital Advisors $36.1M, Baker Bros. Advisors $32.2M.

  • AnalystsBULLISH

    18 of 19 rate it Buy or better. Every target is above the price.

  • Short sellersBUILDING

    Short interest +17.7% to 2.73M shares. 6.3 days to cover, ≈10.6% of shares.

  • TrendDOWNTREND

    62% below its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$86.3M
in new stakes
FundMoveSharesValue
Avoro Capital Advisors LLCNEW1,444,039$36.1M
BAKER BROS. ADVISORS LPNEW1,286,411$32.2M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED1,042,198$26.1M
RA CAPITAL MANAGEMENT, L.P.NEW722,020$18.1M
MARSHALL WACE, LLPDOUBLED206,508$5.2M
UBS Group AGDOUBLED21,541$538.5K
RENAISSANCE TECHNOLOGIES LLCTRIM20,416$510.4K
JANE STREET GROUP, LLCDOUBLED20,117$502.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy11Hold1Sell0Strong Sell0
12-month targets · 13 analysts

Price is below the lowest target. Median implies +503%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
REITERATE
REITERATE
Nov 16, 2026🔒 Fresh data, subscribers only
REITERATE
REITERATE
Nov 10, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 4, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 27, 2026BTIG
REITERATE
REITERATEBuy
Oct 16, 2026William Blair
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$1.2M
bought · 2 insiders
$0
sold · 0 insiders
−61.4%
vs their $24.02 cost
DateInsiderTypeValue
Oct 30, 2026
Parikh Anand Kiran
President and CEO
Oct 30, 2026
GIFT100,000 sh
Oct 23, 2026
Schayowitz Adam
Director
Oct 23, 2026
AWARD25,000 sh
Sep 11, 2026
Vousden Karen H
Director
Sep 11, 2026
AWARD25,000 sh
Jul 21, 2026
Parikh Anand Kiran
President and CEO
Jul 21, 2026
AWARD398,018 sh
Jul 21, 2026
Craver Josiah
PAO
Jul 21, 2026
AWARD30,824 sh
Jul 1, 2026
STEPHENSON BRIAN C
Chief Financial Officer
Jul 1, 2026
BUY$103.0K
Jul 1, 2026
STEPHENSON BRIAN C
Chief Financial Officer
Jul 1, 2026
BUY$14.5K
Jun 30, 2026
STEPHENSON BRIAN C
Chief Financial Officer
Jun 30, 2026
BUY$43.8K

Earnings setup

Estimates
−$0.88
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.88-$0.88–-$0.88-12.1%$0.00
Next Q-$0.89-$0.89–-$0.89+0.0%$0.00
Current FY-$15.60-$15.60–-$15.60-13.2%$0.00
Next FY-$3.67-$4.96–-$2.03+18.3%$0.00

Short side

FINRA· Oct 30, 2026
2,730,889
shares short
+17.7%
vs prior settlement
6.3
days to cover
≈10.6%
of shares outstanding
Trading halts
Jul 15, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Montanova Capital, LLC filed an amended Schedule 13G disclosing a 8.9% passive stake in Faeth Therapeutics as of…
SC 13G/A · Impact 3/10
Nov 10, 2026 Earnings calendar
FTH Q3 2026 Earnings Scheduled · 2026-11-10
Nov 9, 2026 SEC
Faeth Therapeutics reported topline Phase 2 data for PIKTOR (serabelisib + sapanisertib) plus paclitaxel in advanced…
8-K · Impact 6/10
Oct 30, 2026 Insider
Parikh Anand Kiran gifted 100,000 shares
President and CEO
Oct 23, 2026 Insider
Schayowitz Adam was granted 25,000 shares
Director
Sep 11, 2026 Insider
Vousden Karen H was granted 25,000 shares
Director
Jun 30, 2026 Inst.
Avoro Capital Advisors LLC · NEW
1,444,039 shares ($36.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

12 filings · 2 bullish · 1 bearish · 9 neutral
All FTH filing & press-release reports (12)